Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
For me, the issue is one of timing. There are a number of steps to be taken before acquiring market share. That's why I don't see a rush to add shares here. But I sure like this company and where they're going.
Kind regards,
Minding
Agree. A good call following acceptable results. I'll consider adding more perhaps in December.
Kind regards,
Minding
Since my July sale of half my COCP shares, I've been keeping an eye on company news and the stock price. There has been precious little news and the price has continued to retreat.
My gauge for quickly checking the value of biotechs is their market cap. In my July comment(s) I expressed a discomfort with COCP having a market cap close to $1B. Since there's been no change in outstanding shares, as the price drops so too does the market cap. Currently COCP's market cap is 606M, closer to my comfort zone; that is, I believe they are fully valued in this price range.
Normally I do not consider a company that is fully valued to be a 'Buy'. Once a company reaches full value it needs time to build for the next ramp upward.
As a Frost stock distantly related to OPK, COCP is an anomaly. This is, IMO, mainly because momentum traders get involved. But I try not to ride momentum for momentum's sake alone. It's also an anomaly because Frost is a clever companies architect. He mixes and matches to best take advantage of strengths and to strengthen weaknesses. The concern is of being left behind when he makes an adept move.
The net result of all this thinking is that the stock has entered a zone where I am willing to double my shares ... though my preference is to now wait for the stock to base for at least a few months (which I believe it will do.)
That's my story and I'm sticking to it ... for now.
Kind regards,
Minding
Perma-Fix Announces Financial Results and Provides Business Update for the Second Quarter of 2015
ATLANTA, GA -- (Marketwired) -- 08/06/15 --
Perma-Fix Environmental Services, Inc. (NASDAQ: PESI)today announced results for the second quarter ended June 30, 2015.
Company Highlights
Revenue increased 29.2% to $16.4 million compared to Q2 2014
Treatment Segment revenue increased 18.0% compared to Q2 2014
Services Segment revenue increased 61.5% compared to Q2 2014
Gross profit increased 159.0% and gross margin increased to 24.7% compared to 12.3% for Q2 2014
Adjusted EBITDA (as defined below) of $2 million compared to a loss of $0.4 million for Q2 2014
Reaffirms adjusted EBITDA (as defined below) guidance of $6M to $7M for 2015
Achieves $2.8 million increase in net income from continuing operations, net of taxes, to $407,000 or $0.05 per share
Dr. Louis F. Centofanti, Chief Executive Officer, stated, "We are pleased to report continued improvement in our financial results, as evidenced by a 29% increase in revenue and a 159% increase in our gross profit. Revenue in our Treatment Segment increased 18% to $11.1 million due to higher waste volume, while revenue in our Services Segment increased 61.5% to $5.3 million due to new contracts that have been awarded. Moreover, Adjusted EBITDA in the second quarter was $2.0 million, compared to a loss for the same period last year. We attribute this improvement to a combination of top line growth and our successful initiatives to streamline operations. Our second quarter results were impacted by a scheduling change that moved a large shipment into the third quarter, which we have subsequently received. We continue to anticipate improvement in both revenue and profitability in the second half of the year, and reaffirm our prior guidance for adjusted EBITDA in the range of $6 million to $7 million."
Dr. Centofanti continued, "We are also pleased to report a number of important developments within Perma-Fix Medical S.A., our Polish subsidiary, including the expansion of our senior management team and the successful scale-up of our process to produce Technetium-99m ("Tc-99m") from Molybdenum-99 ("Mo-99"). The tests confirmed that the our proprietary resins could withstand higher levels of radiation, up to 4 curies, while producing clinically useful doses of Tc-99m. These results at the 4 curie level mark a major achievement, which has attracted significant interest from within the industry."
Financial Results
Revenue for the second quarter of 2015 was $16.4 million versus $12.7 million for the same period last year. Revenue for the Treatment Segment was $11.1 million compared to $9.4 million for the same period in 2014. Revenue from the Services Segment was $5.3 million versus $3.3 million for the same period in 2014.
Gross profit for the second quarter of 2015 was $4.0 million versus $1.6 million for the second quarter of 2014. Gross margin increased to 24.7% from 12.3% for the same period last year primarily due to increased revenue generated from both segments and a reduction in certain fixed costs.
Operating income for the second quarter of 2015 was $613,000 versus an operating loss of $2.1 million for the second quarter of 2014. Operating loss for the second quarter of 2014 included a non-cash goodwill impairment charge of approximately $380,000 for our Schreiber, Yonley and Associates ("SYA") reporting unit which was divested on July 29, 2014. Net loss attributable to common stockholders for the second quarter of 2015 was $154,000, or ($0.01) per share, versus net income of $11,000 or ($0.00) per share, for the same period in 2014. Net loss attributable to common stockholders for the second quarter of 2015 included a net loss of $713,000 from discontinued operations and net income attributable to common stockholders for the second quarter of 2014 included a net income from discontinued operations of $2.4 million. Loss from discontinued operations for the second quarter of 2015 included a non-cash asset impairment charge of $150,000 on our Perma-Fix Michigan, Inc. property and a penalty payment of approximately $201,200 in connection with certain alleged violations pertaining to our Perma-Fix of South Georgia, Inc. ("PFSG") subsidiary. Income from discontinued operations for the second quarter of 2014 included a gain on insurance settlement of approximately $3.5 million for our PFSG subsidiary.
The Company recorded Adjusted EBITDA of $2.0 million from continuing operations during the quarter ended June 30, 2015, as compared to Adjusted EBITDA loss of $426,000 for the same period of 2014. The Company defines EBITDA as earnings before interest, taxes, depreciation and amortization. Adjusted EBITDA is defined as EBITDA before research and development costs related to the Medical Isotope project and impairment charges on goodwill. Both EBITDA and Adjusted EBITDA are not measures of performance calculated in accordance with Generally Accepted Accounting Principles in the United States of America ("GAAP"), and should not be considered in isolation of, or as a substitute for, earnings as an indicator of operating performance or cash flows from operating activities as a measure of liquidity. The Company believes the presentation of EBITDA and Adjusted EBITDA is relevant and useful by enhancing the readers' ability to understand the Company's operating performance. The Company's management utilizes EBITDA and Adjusted EBITDA as a means to measure performance. The Company's measurements of EBITDA and Adjusted EBITDA may not be comparable to similar titled measures reported by other companies. The table below reconciles EBITDA and Adjusted EBITDA, both non-GAAP measures, to GAAP numbers for income (loss) from continuing operations for the three and six months ended June 30, 2015 and 2014.
Good points bw. Thanks to you and Blane.
Minding
Yahoo doesn't have this. Though Fidelity and TDA do, I hadn't seen it. Thanks for catching me up.
Minding
Blane,
I expected BTEBY to be closer to the offering price than it is and have been surprised to find it well-above. I can't see it having such a differential once BNTC begins trading; they should be closer to lockstep ... which means BNTC may open above the offering price.
I also have not been expecting a drop (too much) below the offering price. Certainly nowhere near 50%. I still don't.
Your explanation is a standard explanation of dilution. It doesn't explain the rise to 14.15 on below-average volume in combination with Panno's statement about dilution. He can parse his words in his reply to my comment if he wishes, but he didn't do so in the article.
Thanks,
Minding
Blane thanks for your response. It doesn't address my question which was directed at what Panno wrote, "For old/existing investors the IPO means a dilution of their holdings. Roughly, a fifty percent dilution. On the surface this is not good ..."
Minding
Perhaps I'm being thick but I find Panno's remarks a bit confusing. If it's dilutive for existing investors why is BTEBY up and well above the offering price of BNTC?
If tomorrow it's going to drop (as a result of dilution), why wouldn't investors sell today and get back in tomorrow?
Kind regards,
Minding
PS I also am posting this as a comment on his article. I'll post his reply if he replies.
Excellent. Thanks.
Minding
I suppose you're right but I don't see shorts being a problem. You've got a stock that has steadily declined since April which I have concluded has indicated dwindling investor patience.
The two prospects in my mind are dilution (need for cash) or a technical issue. If it were technical, the stock would plummet so I've excluded that prospect.
Since yesterday's drop is in line with the overall downward channel, it could be nothing of course.
Kind regards,
Minding
Thanks Blane.
Minding
I hope you're right Jackie. In my experience, a move like that on outsized volume (compared to the average) before a report/CC often suggests someone on or near the inside knows something that the rest of the investment community will discover too late.
At any rate it leaves me feeling uncomfortable leading into tomorrow's call.
Kind regards,
Minding
Do you have a link to shareholder's letter or copy?
Thanks,
Minding
Thx. I tried to get more shares AH but my price was a bit too greedy.
The stock should do fine in anticipation of success. Will success follow? It seems like a solid bet, but only time will tell.
Kind regards,
Minding
I found RMTI via a Stifel's report and posted it here some time ago. Here's their update from yesterday:
https://stifel2.bluematrix.com/sellside/EmailDocViewer?encrypt=5c048233-e1b6-4e01-991e-72ad9b498dbf&mime=pdf&co=Stifel&id=EquityResearch@stifel.com&source=mail
Kind regards,
Minding
I found RMTI via a Stifel's report and posted it here some time ago. Here's their update from yesterday:
https://stifel2.bluematrix.com/sellside/EmailDocViewer?encrypt=5c048233-e1b6-4e01-991e-72ad9b498dbf&mime=pdf&co=Stifel&id=EquityResearch@stifel.com&source=mail
Kind regards,
Minding
I guess it depends upon your timeline. The key point came in from the CEO in the CC:
I'd like to make an important point regarding the Triferic commercial launch, and that is that we know the renal market extremely well. We have been successful in this market launching, selling and delivering products for 20 years. We understand the customer base. We know we need only a handful of salespeople. There are 9 customers that we need to negotiate with who control about 85% of the market, and we have relationships with them that have been built and maintained over 20 years. Negotiations with these customers are being handled directly by senior management. I can tell you that the interest from renal providers in gaining access to Triferic is very strong. As we've stated in the past, this is not a typical drug launch that involves trying to convince individual doctors to write weekly prescriptions. Triferic is part of the bundled reimbursement. Therefore, it is already accounted for in the bundled payment and, as you know, its reimbursement code became effective July 1 this year. As dialysis providers conclude their pilot programs, we anticipate broad adoption over a short period of time.
Kind regards,
Minding
From the CC:
I'd like to make an important point regarding the Triferic commercial launch, and that is that we know the renal market extremely well. We have been successful in this market launching, selling and delivering products for 20 years. We understand the customer base. We know we need only a handful of salespeople. There are 9 customers that we need to negotiate with who control about 85% of the market, and we have relationships with them that have been built and maintained over 20 years. Negotiations with these customers are being handled directly by senior management. I can tell you that the interest from renal providers in gaining access to Triferic is very strong. As we've stated in the past, this is not a typical drug launch that involves trying to convince individual doctors to write weekly prescriptions. Triferic is part of the bundled reimbursement. Therefore, it is already accounted for in the bundled payment and, as you know, its reimbursement code became effective July 1 this year. As dialysis providers conclude their pilot programs, we anticipate broad adoption over a short period of time.
Kind regards,
Minding
CC at 4:40 pm @ http://edge.media-server.com/m/p/6nydkd4u
The inline report means nothing to the stock going forward. It's all about Triferic and hopefully an improving situation for Calcitriol.
Kind regards,
Minding
Rockwell Medical Reports Second Quarter 2015 Results
From http://finance.yahoo.com/news/rockwell-medical-reports-second-quarter-200100182.html
WIXOM, Mich., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the second quarter of 2015.
Q2 2015 Financial Highlights
Sales were $13.0 million, in line with Q2 2014.
Gross profit was $2.1 million, a 2.3% increase over Q2 2014.
Gross profit margins increased to 15.9% compared to 15.5% in Q2 2014.
R&D expense was $0.9 million compared to $0.8 million in Q1 2015.
Net loss was ($2.5) million or ($0.05) per share, compared to a net loss of ($3.2) million or ($0.08) per share in Q2 2014, a $.03 per share improvement.
Cash and investments were $77.3 million as of June 30, 2015.
YTD 2015 Financial Highlights
Sales in the first six months of 2015 were $26.8 million compared to $26.0 million in the first six months of 2014.
Gross profit was $4.4 million, an 18.4% increase over the first six months of 2014.
Gross profit margins increased to 16.3% compared to 14.2% in the first six months of 2014.
R&D expense was $1.7 million compared to $4.8 million in the first six months of 2014.
Net loss was ($6.2) million or ($0.12) per share, compared to a net loss of ($11.0) million or ($0.28) per share in the first six months of 2014, a $0.16 per share improvement.
2015 YTD Corporate Highlights
Obtained U.S. FDA drug approval to market Triferic(TM) (ferric pyrophosphate citrate) for iron replacement and hemoglobin maintenance in hemodialysis patients.
Received U.S. CMS Q-Code assignment for reimbursement of Triferic; effective July 1, 2015.
Increased manufacturing and product inventory ahead of commercial drug launches.
Increased marketing and advertising in preparation for commercial drug launches.
PRIME ESA Sparing Study published in Kidney International.
CRUISE 1-2 Phase 3 Studies published in Nephrology Dialysis Transplantation.
Triferic clinical data presented at the National Kidney Foundation Spring Meeting and Annual Dialysis Conference both in the U.S., and ERA-EDTA Congress in Europe.
"As expected, we had another solid quarter," stated Robert L. Chioini, Chairman and CEO of Rockwell. "Our focus and effort the last five months has been on performing the necessary work to launch Triferic commercially, as well as Calcitriol. Since our FDA approval of Triferic, interest from the clinical community in gaining access to the drug has been strong across large and small dialysis organizations. Short-term pilot evaluations are being coordinated among some of the larger groups to establish internal protocol, prior to clinic-wide use. We anticipate these pilot studies will begin in the next few weeks. Once internal protocols are established and working satisfactorily, we expect to see broad-based clinical adoption of Triferic.
Conference Call Information
Rockwell Medical will be hosting a conference call to review its second quarter 2015 results on Tuesday, August 4, 2015 at 4:30 pm ET. Investors are encouraged to call a few minutes in advance at (877) 383-7438, or for international callers (678) 894-3975, passcode # 82154892 or to listen to the call via webcast at the Rockwell Medical IR web page: http://ir.rockwellmed.com/
About Triferic
Triferic is a unique iron compound that is delivered to hemodialysis patients via dialysate, replacing the ongoing iron loss that occurs during their dialysis treatment. Triferic is introduced into bicarbonate concentrate, on-site at the dialysis clinic, and subsequently mixed into dialysate. Once in dialysate, Triferic crosses the dialyzer membrane and enters the blood where it immediately binds to transferrin and is transported to the erythroid precursor cells to be incorporated into hemoglobin. In completed clinical trials, Triferic has demonstrated that it can effectively deliver sufficient iron to the bone marrow and maintain hemoglobin, without increasing iron stores (ferritin). Please visit www.triferic.com for more information.
About Rockwell Medical
Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis.
Rockwell's recent FDA approved drug Triferic is indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Triferic delivers iron to patients during their regular dialysis treatment, using dialysate as the delivery mechanism. In completed clinical trials, Triferic has demonstrated that it safely and effectively delivers sufficient iron to the bone marrow and maintains hemoglobin, without increasing iron stores (ferritin). Rockwell intends to market Triferic to hemodialysis patients in the U.S. dialysis market.
Rockwell's FDA approved generic drug Calcitriol is for treating secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy. Rockwell intends to market Calcitriol to hemodialysis patients in the U.S. dialysis market.
Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell's products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. Rockwell has three manufacturing/distribution facilities located in the U.S.
Rockwell's exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of Triferic for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information.
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Rockwell's intention to launch Calcitriol and Triferic following FDA approval. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan", "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical's SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
KDUS: This sounds interesting and I appreciate the lead. There is no confirmation of Frost's involvement at Insider Trading going back to January 1, 2000.
Here's KDUS:
http://insidertrading.org/?sort_by=acceptance_datetime&asc=&symbol=kdus&date_from=2000-01-01&date_to=2015-08-03&submit=+GO+
Proof that the site works, here's COCP:
http://insidertrading.org/?sort_by=acceptance_datetime&asc=&symbol=cocp&date_from=2000-01-01&date_to=2015-08-03&submit=+GO+
If anyone has a link accessible to everyone (not just subscribers) that documents Frost's involvement with KDUS, please provide it.
Many thanks and kind regards,
Minding
Very helpful thoughts Steve. You display a solid grasp of Frost-related investing and I appreciate it.
Kind regards,
Minding
This is a very useful comment Steve. It distills some of what BLRX is all about by giving a specific example in the form of COCP. It would be useful to post it on the BLRX board also and perhaps expand on it if you've got more to say.
Kind regards,
George
SciVac Therapeutics Announces Precautionary Recall of Sci-B-Vac
When investing, it's best to do so with eyes open.
Kind regards,
Minding
===============
Marketwired SciVac Therapeutics Inc.
2 hours ago
????
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jul 30, 2015) - SciVac Therapeutics Inc. ("SciVac" or the "Company") (VAC.TO)(SVACF) announced today that, following discussions with the Israeli Ministry of Health (the "IMOH"), it is recalling from the market all Sci-B-Vac™ sold by the Company from January 1, 2012 to the present.
The Company is carrying out the recall solely as a precautionary measure, as, following inspection by SciVac, it was determined that certain unshipped packages of the Sci-B-Vac™ hepatitis B vaccine contained a small number of damaged vials. SciVac then reported its findings to the IMOH. There have been no reports of harm to any patients, nor have there been any reports with respect to Sci-B-Vac's™ efficacy or safety. Currently, the Company believes that an issue in the labeling process caused the damage, and the IMOH informed the Company that it may continue manufacturing Sci-B-Vac™ uninterrupted, so long as the Company uses an alternative labeling process until the issue can be appropriately remedied. The Company is diligently investigating the failure that resulted in the damaged vials.
The recall primarily affects the Israeli and Hong Kong markets.
About SciVac Therapeutics Inc.
SciVac Therapeutics Inc., headquartered in Rehovot Israel, is in the business of developing, producing and marketing biological products for human healthcare. The Company's flagship product, Sci-B-Vac™, is a recombinant 3rd generation hepatitis B vaccine. The Company also has in-licensed an early-stage enzyme-based product designated S-Graft, which is a recombinant human deoxyribonuclease I, a repurposed biological therapeutic intended for the prevention and treatment of graft-versus-host disease (GVHD). The Company also offers contract development and manufacturing services to the life sciences and biotechnology markets.
Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX), the Frankfurt Stock Exchange nor the OTCQX accepts responsibility for the adequacy or accuracy of this news release.
Cautionary Statement on Forward-looking Information
Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding the expected effect of the product recall on the Company's business are forward-looking statements that involve various risks and uncertainties.
Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: market reaction to the recall, the effect of the recall on the use of Sci-B-Vac™ vaccine, the effect on the Company's operations of rectifying the issues that lead to the recall, litigation or regulatory action relating to the recall, the effect of the recall on the Company's actual financial results, general economic conditions and other factors detailed from time to time in the Company's periodic disclosure. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on the Company's current expectations and it undertakes no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.
Contact:
SciVac Therapeutics Inc.
Curtis Lockshin
Chief Executive Officer
+972-8-948-0625
lockshin@scivactherapeutics.com
www.scivactherapeutics.com
Well worth listening. Thanks to you and Blane.
Kind regards,
Minding
DavenCT, thanks for the boot-on-the-ground report.
Perhaps your brother is thinking of CelleRX (http://www.cellerx.com/about.html)?
Their third product is a skin and wound cleanser (http://www.neutrophase.com).
Kind regards,
Minding
Temporary pop as in April Steve.
=========
From http://finance.yahoo.com/news/medicinova-announces-fda-approval-second-120000112.html
MediciNova Announces FDA Approval of the Second Phase 2 Protocol for MN-001 in NASH Which Targets NASH Patients With Hypertriglyceridemia
MediciNova, Inc.
1 hour ago
GlobeNewswire
????
LA JOLLA, Calif., July 27, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that FDA (U.S. Food and Drug Administration) has approved a second protocol for a clinical trial evaluating MN-001 (tipelukast) for a NASH indication. This study targets NASH patients with hypertriglyceridemia to evaluate the ability of MN-001 to improve cardiovascular risk by assessing cholesterol-efflux capacity and serum triglyceride levels as well as reduction of percent fat in the liver, as assessed by MRI.
Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc., commented, "We are very pleased to have successfully completed the FDA review period and look forward to initiating patient enrollment shortly. The safety and efficacy data from this trial will be important to our overall development efforts targeting NASH and should be complementary to efforts underway. In previous clinical trials and preclinical studies, serum triglyceride levels were reduced in MN-001-treated groups. It is well known that NASH patients often have elevated serum lipid levels, one of the factors that contribute to cardiovascular disease. Recent studies have confirmed that cardiovascular disease is the single most important cause of mortality in this patient population. Importantly, MN-001's anti-fibrotic properties combined with its potential to reduce triglyceride levels in NASH patients offers a novel approach to the treatment of NASH."
About the Study Design
The Phase 2 trial is a single-center, proof-of-principle, open-label study designed to evaluate the efficacy, safety, and tolerability of MN-001 in subjects with nonalcoholic steatohepatitis (NASH) and hypertriglyceridemia. Eligible subjects will consist of males and females ranging in age from 21 to 65 years old, inclusive. To be eligible, subjects must have a histologically confirmed diagnosis of NASH within 6 months prior to the baseline visit and an elevated serum triglyceride (> 150 mg/dL) during the Screening Phase. Approximately twenty (20) qualifying subjects will be given MN-001 250 mg orally administered once a day for the first 4 weeks and will be given MN-001 250 mg twice a day for an additional 8 weeks. Overall, the study timeline consists of a Screening Phase (up to 4 months) followed by a Treatment Phase (12 weeks), and a Follow-up visit (within 1 week after the last dose).
The primary efficacy endpoints of the study are to evaluate the effect of MN-001 on 1) Triglyceride levels in NASH subjects with hypertriglyceridemia, and 2) Cholesterol Efflux Capacity in NASH subjects with hypertriglyceridemia. Secondary endpoints include safety and tolerability of MN-001, PK profile of MN-001/MN-002 (by-product of MN-001), effects of MN-001 on HDL-C, LDL-C, and total cholesterol level, and effects of MN-001/002 on liver enzymes and percent fat in liver assessed using MRI at Week 12.
Earlier this year, the FDA granted Fast-Track designation to MN-001 for the treatment of NASH with fibrosis. Fast Track is a process designed to facilitate the development and expedite the review of drugs that are intended to treat serious or life-threatening diseases and demonstrate the potential to address unmet medical needs for such diseases. An important feature of the FDA's Fast Track program is that it emphasizes frequent communication between the FDA and the sponsor throughout the entire drug development and review process to improve the efficiency of product development. Accordingly, Fast Track status can potentially lead to a shortened timeline to ultimate drug approval.
Related Quotes
MNOV
4.89
+39.32%
MediciNova Inc.? Watchlist
4.89+1.38(39.32%)
NASDAQ9:57 AM EDT
MEDICINOVA INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits EDGAR Online 24 days ago
MEDICINOVA INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online 1 mth 12 days ago
More
About Nonalcoholic Steatohepatitis
Nonalcoholic steatohepatitis (NASH) is a condition in which there is fat in the liver along with inflammation and damage to liver cells. NASH is a common liver disease that resembles alcoholic liver disease but occurs in people who drink little or no alcohol. According to the U.S. National Digestive Diseases Information Clearinghouse (NDDIC), NASH prevalence in the U.S. is 2-5%, and an additional 10-20% of Americans have "fatty liver." The underlying cause of NASH is unclear, but it most often occurs in people who are middle-aged and overweight or obese. Many patients with NASH have elevated serum lipids, diabetes or pre-diabetes. Progression of NASH can lead to liver cirrhosis. Liver transplantation is the only treatment for advanced cirrhosis with liver failure. At this time, there is no treatment for NASH.
About MN-001
MN-001 (tipelukast) is a novel, orally bioavailable small molecule compound thought to exert its effects through several mechanisms to produce its anti-inflammatory and anti-fibrotic activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO). The 5-LO/LT pathway has been postulated as a pathogenic factor in fibrosis development and MN-001's inhibitory effect on 5-LO and the 5-LO/LT pathway is considered to be a novel approach to treat fibrosis. MN-001 has been shown to down-regulate expression of genes that promote fibrosis including LOXL2, Collagen Type 1 and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation including CCR2 and MCP-1. In addition, histopathological data shows that MN-001 reduces fibrosis in multiple animal models.
Previously, MediciNova evaluated MN-001 for its potential clinical efficacy in asthma and had positive Phase 2 results. MN-001 has been exposed to more than 600 subjects and is considered generally safe and well-tolerated. Importantly, in these studies, reduction of serum triglyceride was observed for those treated with MN-001 in healthy volunteers and target populations.
About MediciNova
MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a commercial focus on the U.S. market. MediciNova's current strategy is to focus on MN-166 (ibudilast) for neurological disorders such as progressive MS, ALS and substance dependence (e.g., methamphetamine dependence and opioid dependence), and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). MediciNova's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbations of asthma and MN-029 (denibulin) for solid tumor cancers. MediciNova is engaged in strategic partnering and other potential funding discussions to support further development of its programs. For more information on MediciNova, Inc., please visit www.medicinova.com.
Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166, MN-221, MN-001 and MN-029. These forward-looking statements may be preceded by, followed by or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," "considering," "planning" or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166, MN-221, MN-001 and MN-029, risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2014 and its subsequent periodic reports on Forms 10-Q and 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.
Contact:
If only posts could be deleted when posted on the wrong board!
Minding
BLRX is not down in sympathy with the markets.
There's no getting around the bad news in this press release. However if Savitsky isn't blowing smoke, this is a buying opportunity for the longer term view.
Kind regards,
Minding
=========
From http://finance.yahoo.com/news/biolinerx-announces-top-line-results-101000916.html
BioLineRx Announces Top-Line Results from Bellerophon’s PRESERVATION I Clinical Trial for Bioabsorbable Cardiac Matrix (BL-1040)
Business Wire BioLineRx Ltd.
3 hours ago
????
TEL AVIV, Israel--(BUSINESS WIRE)--
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its partner, Bellerophon, reported top-line results from its PRESERVATION I clinical trial for Bioabsorbable Cardiac Matrix (BCM). BCM, also known as BioLineRx’s BL-1040, is an investigational, implantable medical device being studied for the prevention of heart failure following an acute myocardial infarction (AMI), commonly known as a heart attack.
The 303-patient, randomized, double-blinded, placebo-controlled study showed no statistically significant difference between patients treated with BCM versus placebo for both the primary and the secondary endpoints.
BL-1040 was licensed to Bellerophon, then known as Ikaria, in 2009. Prior to partnering the project, BioLineRx invested slightly over $10 million in the development of BL-1040. To date, BioLineRx has received a total of $17 million for this asset under the license agreement.
“While we share in Bellerophon’s disappointment with the BCM results, we believe BioLineRx’s true value remains in our ability to advance our deep in-house pipeline of mid-late stage assets, including future programs under our strategic collaboration with Novartis, and in particular, our expanding BL-8040 oncology platform,” said Dr. Kinneret Savitsky, CEO of BioLineRx. “We are on track to report top-line data from our Phase 2 clinical study of BL-8040 for treating relapsed/refractory AML in Q4 2015. Results from the dose escalation phase of this study demonstrated potential best-in-class mobilization of cancer cells from the bone marrow, as well as significant induction of cancer cell death. Additionally, we reported positive safety and efficacy results from a Phase 1 study for BL-8040 as a novel stem cell mobilization treatment for transplantation. We expect to meet with the FDA in order to discuss our next steps in the clinical development program for this indication, including the design of a planned follow-up Phase 2 study. We are also in preparations to initiate three additional Phase 2 studies for BL-8040 in consolidation AML, in AML patients with the FLT3-ITD mutation, and for hypoplastic myelodysplastic syndrome and aplastic anemia. We eagerly anticipate reaching several key inflection points for our BL-8040 platform over the next 12 months, which we hope will add significant value for BioLineRx and our shareholders.”
Dr. Savitsky continued, “We remain well capitalized to achieve our corporate and clinical goals through 2018. So while today’s news is unfortunate, we believe it has minimal impact on our business as a whole and our plans going forward. We look forward to Bellerophon presenting the full study data at the upcoming European Society of Cardiology’s annual meeting and to providing the next steps for this program.”
About PRESERVATION I
PRESERVATION I evaluated the safety and effectiveness of BCM for the prevention of ventricular remodeling and heart failure when administered to subjects who had successful PCI with stent placement after ST-Elevation Myocardial Infarction (STEMI). In the study, subjects were randomized to receive BCM (active treatment) or saline control (placebo treatment) in a 2:1 ratio, two to five days following the initial PCI.
The primary endpoint for PRESERVATION I was the change in Left Ventricular End Diastolic Volume Index (LVEDVI) at six months compared to baseline. LVEDVI is an anatomical measurement of ventricular remodeling that was measured by 3-D and 2-D echocardiography. The secondary endpoints for PRESERVATION I were the Kansas City Cardiomyopathy Questionnaire (KCCQ) (summary score); six-minute walk test (6MWT); New York Heart Association (NYHA) functional classification (physician reported); time to cardiovascular death, non-fatal heart failure events or cardiovascular hospitalizations adjudicated by a Clinical Events Committee; and time to first re-hospitalization due to any cardiovascular event.
Safety was evaluated based on adjudication of cardiac serious adverse events by an independent Clinical Events Committee (CEC), as well as periodic reviews conducted by an independent Data Monitoring Committee (DMC).
About BioLineRx
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.
BioLineRx’s current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-8040, a cancer therapy platform, which is in the midst of a Phase 2 study for acute myeloid leukemia (AML), and has successfully completed a Phase 1 study in stem cell mobilization; BL-7010 for celiac disease, which has successfully completed a Phase 1/2 study; and BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Bellerophon BCM (f/k/a Ikaria).
In December 2014, BioLineRx entered into a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates. The companies intend to co-develop a number of pre-clinical and early clinical therapeutic projects through clinical proof-of-concept for potential future licensing by Novartis.
For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company’s SEC documents, press releases, and events. BioLineRx’s IR app is available on the iTunes App Store as well as the Google Play Store.
Various statements in this release concerning BioLineRx’s future expectations constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as “may,” “expects,” “anticipates,” “believes,” and “intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the “Risk Factors” section of BioLineRx’s most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 23, 2015. In addition, any forward-looking statements represent BioLineRx’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150727005497/en/
Contact:
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D., +1-212-375-2664
jdrumm@tiberend.com
or
Andrew Mielach, +1-212-375-2694
amielach@tiberend.com
or
BioLineRx Ltd.
Tsipi Haitovsky, +972-3-6240871
Public Relations
tsipihai5@gmail.com
MNOV having a nice morning.
Remember however it performed this way back in April. This is a WIP.
Kind regards,
Minding
Perma-Fix Announces That Its Subsidiary, Perma-Fix Medical S.A., Has Completed Its Strategic Partnership and Investment From Digirad Corporation
Marketwired Perma-Fix Environmental Services, Inc.
1 hour ago
From http://finance.yahoo.com/news/perma-fix-announces-subsidiary-perma-120000466.html
ATLANTA, GA--(Marketwired - July 27, 2015) - Perma-Fix Environmental Services, Inc. (PESI) today announced that its Polish subsidiary, Perma-Fix Medical, S.A., has completed its previously announced strategic partnership and investment from Digirad Corporation, one of the largest national providers of in-office nuclear cardiology imaging services. Digirad uses Technetium-99m (Tc-99m) in its nuclear imaging services business and provides imaging expertise to the medical community.
Under this partnership, Digirad invested $1 million into Perma-Fix Medical S.A., which is a publicly traded company listed on the NewConnect market of the Warsaw Stock Exchange. The investment constituted approximately 5.4% of the outstanding common shares of Perma-Fix Medical S.A. As part of the partnership and investment, Digirad appointed Matt Molchan, President and CEO of Digirad Corporation, to Perma-Fix Medical S.A.'s Supervisory Board. As part of the partnership, upon successful completion of development of the new Tc-99m resin, Digirad will purchase agreed upon quantities of Tc-99m for its nuclear imaging operations either directly or in conjunction with its preferred nuclear pharmacy supplier and Perma-Fix Medical S.A. will supply Digirad or its preferred nuclear pharmacy supplier with Tc-99m at a preferred rate.
Steve Belcher, CEO of Perma-Fix Medical S.A., commented, "We are pleased to have finalized our agreement with Digirad, which we believe will help accelerate development and commercialization of our new proprietary process to produce Tc-99m without the use of uranium. This new process does not use either highly enriched uranium (HEU) or low enriched uranium (LEU), and therefore addresses the major industry challenges of the current process, including waste production, proliferation risk, and a stable supply chain. As one of the leading users of Tc-99m, Digirad is an ideal partner with extensive industry knowledge and expertise to help finalize our development."
Dr. Centofanti, President and CEO of Perma-Fix Environmental Services, Inc. continued, "We are pleased to move forward with our strategic partnership with Digirad, especially in light of our recent tests at the 4 curie level, which confirmed that our proprietary resins could withstand higher levels of radiation. This milestone has gained significant attention within the industry and we are moving forward rapidly with plans to establish additional partners involved in the supply chain."
Matt Molchan, President and CEO of Digirad, commented, "Perma-Fix Medical S.A. has made significant progress since we began our relationship and we look forward to working closely with them to bring this transformation process to market. We believe the Perma-Fix Medical S.A. process can develop into the standard of production of Tc-99m for many years into the future."
About Tc-99m
Tc-99m is the most widely used medical isotope in the world. It allows medical practitioners to image internal body organs and is used in 80%-85% of the 25 million diagnostic nuclear medical procedures each year in the U.S. alone. Common procedures include: cardiac imaging; cancer detection; bone scans; gastrointestinal issues; imaging of the brain, kidney, spleen; and imaging for infections. The radioisotope market in Europe alone is expected to reach $1.6 billion in 2017, up from $1.1 billion in 2012.
Nearly all of the world's supply of Tc-99m comes from the thermal fission of HEU targets in a small number of highly specialized reactors. The current process is costly and from time to time, has experienced disruptions which has resulted in short-term shortages. The current process also raises serious proliferation concerns related to the threat associated with international production, transportation and/or use of HEU in the production of medical isotopes.
Perma-Fix Medical S.A.'s technology overcomes these issues by using neutron capture to activate natural molybdenum, a common metal, to produce Molybdenum 99 (Mo-99), which decays into Tc-99m. Unlike conventional processes, the Perma-Fix Medical S.A. process can be produced locally using standard research and commercial reactors, thereby eliminating the need for special purpose reactors. The new process encompasses the full production cycle, from reactor to final medical supply, and should be easily deployable around the world within the current industry infrastructure.
To overcome past issues with neutron activation of Mo-99, Perma-Fix Medical S.A. has developed a specialized resin that is radiation resistant and holds large quantities of Mo-99, but at the same time releases almost 90% of the Tc-99m as it forms from the decay of Mo-99. The resin, loaded with the activated Mo-99, is placed in a technetium generator and slowly washed with a saline based solution. The eluent solution containing Tc-99m has been shown to meet targeted United States Pharmacopeia (USP) standards for pertechnetate.
About Digirad
Digirad delivers convenient, effective, and efficient diagnostic solutions on an as needed, when needed, and where needed basis. Digirad is one of the largest national providers of in-office nuclear cardiology and ultrasound imaging services, and also provides cardiac event monitoring services. These services are provided to physician practices, hospitals and imaging centers through its Diagnostic Services business. Digirad also sells medical diagnostic imaging systems, including solid-state gamma cameras, for nuclear cardiology and general nuclear medicine applications, as well as provides service on the products sold through its Diagnostic Imaging business. For more information, please visit www.digirad.com. Digirad® and Cardius® are registered trademarks of Digirad Corporation.
About Perma-Fix Medical S.A.
Perma-Fix Medical S.A. is a subsidiary of Perma-Fix Environmental Services Inc., a NASDAQ listed company. It was formed to develop, obtain U.S. Food and Drug Administration (FDA) and other regulatory approvals and commercialize a new process to produce Tc-99m, the most widely used medical isotope in the world. The new process is expected to solve worldwide shortages of Tc-99m as it is less expensive, does not require the use of government-subsidized, weapons-grade materials and can be easily deployed around the world using standard research and commercial reactors, thereby eliminating the need for special purpose reactors. Please visit Perma Fix Medical S.A. at http://www.medical-isotope.com.
About Perma-Fix Environmental Services
Perma-Fix Environmental Services, Inc. is a nuclear services company and leading provider of nuclear and mixed waste management services. The Company's nuclear waste services include management and treatment of radioactive and mixed waste for hospitals, research labs and institutions, federal agencies, including the Department of Energy (DOE), the Department of Defense (DOD), and the commercial nuclear industry. The Company's nuclear services group provides project management, waste management, environmental restoration, decontamination and decommissioning, new build construction, and radiological protection, safety and industrial hygiene capability to our clients. The Company operates four nuclear waste treatment facilities and provides nuclear services at DOE, DOD, and commercial facilities nationwide. Please visit Perma Fix Environmental Service at http://www.perma-fix.com.
This press release contains "forward-looking statements" which are based largely on the each company's expectations and are subject to various business risks and uncertainties, certain of which are beyond each company's control. Forward-looking statements generally are identifiable by use of the words such as "believe", "expects", "intends", "anticipate", "plans to", "estimates", "projects", and similar expressions including, validation of the Perma-Fix Medical S.A. technology, development and commercialization of the Tc-99m process and the benefits of such process. These risks are detailed in Perma-Fix Environmental Services and Digirad Corporations' filings with the U.S. Securities and Exchange Commission, including the Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other reports. Readers are cautioned to not place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and each company undertakes no obligation to revise or update the forward-looking statements contained herein.
Contact:
For Perma-Fix Environmental Services and Perma Fix Medical
David K. Waldman
US Investor Relations
Crescendo Communications, LLC
(212) 671-1021
Herbert Strauss
European Investor Relations
herbert@eu-ir.com
+43 316 296 316
For Digirad Corporation
Jeffry Keyes
Chief Financial Officer
(858) 726-1600
ir@digirad.com
Rockwell Medical Schedules Second Quarter Earnings Call
Rockwell Medical, Inc.
57 minutes ago
GlobeNewswire
????
WIXOM, Mich., July 27, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it will hold its quarterly conference call to discuss second quarter 2015 financial results on Tuesday, August 4, 2015 at 4:30pm Eastern Time.
This call is also being webcast and can be accessed at the Rockwell Medical Investor Relations web page. You can join this call on:
Date: Tuesday, August 4
Time: 4:30pm ET
Dial in number: (877) 383-7438
International dial in: (678) 894-3975
Passcode: 82154892
Webcast: http://ir.rockwellmed.com
Sigma Labs Announces Second Quarter Conference Call
From an email:
SANTA FE, N.M. – July 27, 2015 – Sigma Labs, Inc. (OTCQB: SGLB) (“Sigma Labs” or the “Company”), a developer of advanced, in process, non-destructive quality inspection systems for metal-based additive manufacturing and other advanced manufacturing technologies, today announced that it will host a conference call to discuss the financial results for the Company's second quarter of fiscal 2015. The conference call will be held Friday, August 7, 2015, at 11:00 a.m. Eastern Time. Sigma Labs plans to release the Company's 2015 second quarter results prior to market open that same day, August 7, 2015.
To participate in the call, please dial toll free 1-888-243-4451, or 1-412-542-4135, approximately five minutes before the conference call time stated above. A live webcast of the call can also be accessed on the Sigma Labs website at www.sigmalabsinc.com. A recording will be available on the Company's website upon completion of the call.
About Sigma Labs, Inc.
Sigma Labs, Inc., through its wholly-owned subsidiary B6 Sigma, Inc., develops and engineers advanced, in-process, non-destructive quality inspection systems for commercial firms worldwide seeking productive solutions for metal-based additive manufacturing or 3D printing, and other advanced manufacturing technologies. For more information please visit us at www.sigmalabsinc.com.
Investor Relations Contact:
Chris Witty
cwitty@darrowir.com
646-438-9385
Good point Steve. Thanks.
George
I reviewed my post to try understanding why sublover would think I was bashing COCP. I have concluded it may be because I didn't add supportive information to my conclusion that their work doesn't warrant a 782M market cap or a big move from here (unless there is revelatory news).
At the Cocrystal Pharma website under the Programs tab, management shows five programs under development. Under three of the five, they have a Developmental Timetable section. The two programs without a timetable say only that scientists have identified compounds which is a pre-Phase I step.
A third one says they are selecting a lead compound for clinical development, also pre-Phase I. The fourth and fifth timetables refer to Phase I safety studies beginning by late 2015.
What moves a company's stock at this point in its lifecycle? In my opinion, it's unexpected news, dilution, or momentum traders.
I sold shares in my taxable account because that's a trading account. I have not yet sold shares in my IRA because a) it didn't hit my price and b) I hold out faint hopes for unexpected news.
That's where things stand for me right now.
Anyone here who asks for clarification, more facts, more information, a better explication of an investor's post is doing a service to the rest of us.
Kind regards,
Minding
Agree Q. The one difference for me is that In my biotech approach I care mainly about market cap, cash, and news (about the company, management, pipeline, etc) because most if not all of the ones I trade don't have products or revenues.
Kind regards,
Minding
SL, I apologize if I have hurt you in any way. That was not my intent.
As to what and how I post, I consider it invaluable to post and to read positive or negative (accurate) information on stocks and positive or negative opinions as long as they're backed up with facts and/or intelligent reasoning.
I am not concerned about reprisal by other investors who might disagree with me. In my opinion these boards are all about sharing as intelligently as one can and hopefully getting that in return since it's rare for opinions of multiple investors to be in sync.
I doubt that my misgivings about COCP will move the stock one way or the other. Frost-o-philes feel insulated; I don't. I stick with my biotech system which focuses in part on market cap relative to the phases of development even with Frost stocks.
You are correct however, I certainly did not get the entire COCP run-up or, as someconerns knows, OPK's, though it was recommended to me early on. I'm not overly concerned. There will be other investments. Even other Frost investments. Including SVON and MBVX and VAC.
Anyway your anger serves no useful purpose here, proves nothing, and causes unnecessary strain. I wish you great fortune with COCP ... and me as long as I hold any shares.
Kind regards,
Minding
FYI: The reason I got out of LVNVF the other day is because I don't want shares of a losing mining company which is, by my DD, what Levon was before Frost bought in. My concern is that it will be difficult to get rid of the mining shares after the split. I decided to exit and buy VAC when it begins publicly trading on the 14th.
Kind regards,
Minding
Thanks Q. Hadn't seen this.
Minding